Tourmaline Bio (TRML) Income Statement (2023 - 2025)
Income Statement report data from Dec 31, 2023 to Jun 30, 2025 for Tourmaline Bio (TRML).
Reported currency: USD
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||
Research And Development | 20M (-3.11%) | 20M (-1.41%) | 21M (+6.31%) | 19M (+22.89%) | 16M (+38.22%) | 11M (+41.90%) | 8.02M |
Selling General And Administrative | 6.34M (+6.20%) | 5.97M (+13.50%) | 5.26M (+2.94%) | 5.11M (-18.11%) | 6.24M (+1.63%) | 6.14M (-10.76%) | 6.88M |
Operating Expenses | 26M (-0.99%) | 26M (+1.63%) | 26M (+5.61%) | 24M (+11.24%) | 22M (+25.40%) | 18M (+17.66%) | 15M |
Operating Income | |||||||
Operating Income | -25.97M (-0.99%) | -26.23M (+1.63%) | -25.81M (+5.61%) | -24.44M (+11.24%) | -21.97M (+25.40%) | -17.52M (+17.66%) | -14.89M |
EBITDA | -25.96M (-0.99%) | -26.22M (+1.63%) | -25.80M (+5.56%) | -24.44M (+11.29%) | -21.96M (+25.41%) | -17.51M (+17.67%) | -14.88M |
Other Income / Expenses | |||||||
Other Non Operating Income | 2.88M (-11.66%) | 3.26M (-8.68%) | 3.57M (-16.20%) | 4.26M (-4.91%) | 4.48M (+6.41%) | 4.21M (+111.56%) | 1.99M |
Net Income | |||||||
Income Before Tax | -23.09M (+0.52%) | -22.97M (+3.33%) | -22.23M (+10.16%) | -20.18M (+15.38%) | -17.49M (+31.40%) | -13.31M (+3.18%) | -12.90M |
Net Income From Continuing Operations | -23.09M (+0.52%) | -22.97M (+3.33%) | -22.23M (+10.16%) | -20.18M (+15.38%) | -17.49M (+31.40%) | -13.31M (+3.18%) | -12.90M |
Net Income | -23.09M (+0.52%) | -22.97M (+3.33%) | -22.23M (+10.16%) | -20.18M (+15.38%) | -17.49M (+31.40%) | -13.31M (+3.18%) | -12.90M |